Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings LSE:SAR London Ordinary Share GB00B02RFS12 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.025p -3.13% 0.775p 0.75p 0.80p 0.80p 0.775p 0.80p 6,926,803 09:13:32
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.2 -0.0 - 20.50

Sareum Share Discussion Threads

Showing 27851 to 27870 of 27875 messages
Chat Pages: 1115  1114  1113  1112  1111  1110  1109  1108  1107  1106  1105  1104  Older
DateSubjectAuthorDiscuss
23/8/2017
18:13
For me,revenue for H2 will be the $550k milestone- or as they said in the interims £450k ; there are the unspent balances of £200k which I guess will be taken into the P&L as they were expensed even if not received by June 30. There are no other revenues I can see so that would make revenues of £650k I have operating costs down for H2 at £600k-lower than the £750K for H1 but still higher than in the past. This figure, which is educated guesswork, depends on how much they spent on the TYK programmes which is hard to read. This back of the envelope calculations would suggest a H2 profit of £50k which allied to the H1 profit of £573k would be more than the modest profit they suggested in the interims. Perhaps they have spending more on the TYK’s than I have thought. All that said when they publish the full year results my primary focus will be on what they say on Aurora; my secondary on the two TYK and my tertiary on profits which are somewhat academic and indeed the level of cash is for me a more important financial matrix. Be interested to hear how others see it
cerrito
23/8/2017
11:22
Cerrito. What is your expectation of profit and cash figure as you are one of the few posters on here who closely monitors the financials? A
ackkers
22/8/2017
11:25
Lol - Monty is a lovable rogue, spends a shedload of hours on here and makes about £3 a year? I like the guy - he makes me smile....Cant wait for his Rocket to make an appearance.
barkboo
22/8/2017
11:18
Did I mention the scaffolders are never wrong - normal early stage MM/Gangster reaction to scare the feeble...we will see a nice move over the next few months. Poor movement this morning! Cerrito - disagree with your post. Put your money on scaffolders being correct.
barkboo
22/8/2017
09:00
ho ho ho hissey fevvers
wolf4
22/8/2017
08:13
Cheers Goosey. You're the best. LOL
norma_stitts
22/8/2017
08:02
should go well over a penny now
king kong dong
22/8/2017
07:53
For me this is one of the cases having cash and profits ahead of market expectations is bad news. It means that their YYK programmes are going slowly and indeed there will be no news till publication of finals it seems. Furthermore given the secrecy of the deal with Sierra the market presumably had no expectations of timing of milestone payments.
cerrito
21/8/2017
22:28
Hi Goosey. See your rehab isn't going too well. Still hammering the Skol I see. Any closer to a liver transplant yet?
norma_stitts
21/8/2017
19:56
ho ho ho what have we here a CEO who promises updates and does not deliver looking around for a new chairman are we dr mitchell someone who will spend a little more than ten minutes a week on sareum this company - listed on AIM is being run by directors mitchell and reader who never buy shares and repeatedly fail to keep promises or do what they say they will do and i stand by that statement AGM will be hectic if these two directors do not deliver on china aurora on usa tyk
goose feathers
21/8/2017
19:51
ho ho ho what have we here- whatever happened the updates Mitchell you going to deliver or are you incapable of telling investors at proactive investors the truth are you going to stand by that statement and just as you asked yorkville to fund your lifestyle- a deal before the end of the year really meant a deal to secure your salary validate your SRI work --where is lead optimisation why dont you tweet something perhaps aCEO like at sierra might take it from you - perhaps not validate your half million- and the bucket shop boys like mrsapesstockingtops and hippyholyhopkirkirk and even andythemkdon will be able to ramp your shares no news is good news - ha ha ha ha - dont hear that from the bucket shop boys anymore thats why the only reason you are surviving is because you are feeding from chk 1 developed by cruk/icroff -
goose feathers
21/8/2017
19:41
ho ho ho what have we here Sierra oncology presentation and out comes one of the duo directors on £500000 half a million to TWEET ?tell investors about it pity Reader couldn't give an update on the sareum projects - but that would be asking too much pity Reader couldn't say what was happening in China 4 years now pity Reader couldn't say anything about SRI NOTHING about sareum mentioned by sierra and Reader wasn't placed on the advisory panel and sareum didnt discover the drug contrary to what some people pretend so why is he receiving half a million along with mitchell and a bell of and ass~~~~ on the other bb quoting notorious freemason franklin- to keep mithchell on the square ho ho ho straight out of the fm playbook-
goose feathers
18/8/2017
17:12
I thought a good and clear webcast which concentrated on 737; I managed to follow the science a bit further than I usually do. Worth listening to; interesting that they are the only publicly quoted company outside big pharma that is in the CHK1 space. Repeated in Feb 18 we will be getting a prelim R&D update. I note that had cash in hand of $116m at 6.17 and a current marcap of $78m- is this discrepancy normal? Or does it represent a greater amount of investor scepticism than normal? Mentioned that Eli Lilley with their LY 2606368 are in the same space
cerrito
16/8/2017
16:22
investor.sierraoncology.com/events-and-webcasts?item=16 :)
skez13
15/8/2017
12:11
For those interested Sierra have established a Scientific Advisory Council with Ivy League and ICR academics.
cerrito
03/8/2017
21:51
Since we are ten years in. And someone else funding the trials. Looking good then
mrsapeslaptop
03/8/2017
11:33
A lot of dreamers on here, 11 years and £1 billion to get a new drug to market.
montyhedge
03/8/2017
10:07
There will be an interesting situation when they present the full year results as my reading is that they have spent virtually nothing on R&D in Calendar H1 2017 ie nothing on ex-CHK1 or Aurora; as far as I can determine for SAR-20347 SRI via the US Taxpayer is paying for all the biology work and for TYK Leukemia that is being essentially covered by UK Innovate. One consequence will be a reduction in R&D Tax Credits-which produced a useful £184k in the last financial year. May buy some more if it drifts lower. PS I am not sure what their deal is with SRI if what they are doing together ever approaches anything near commercialization. A question for the AGM
cerrito
02/8/2017
19:19
I am not really surprised with the share price drifting down as we are in rather a no man’s land ref news at the moment. I see that Sierra are making a presentation on August 15 for which there will be a live audio webcast and will be interesting to hear what they say ref their timing for Phase 1 results-their last word in May was that they anticipate giving an initial update of the trails in early 2018. It would be nice to think that SAR will have hard news on Aurora before they publish their final results end October/early November; for me that would be a pleasant surprise. I would certainly hope before the finals come out we would have had hard news on how SRI are getting on with SAR-20347 and some indication of where we are with TYK2/T-ALL
cerrito
01/8/2017
09:25
Sneaking suspicion we are going to see a blue day soon ........ WOBH
waleoilbeefhooked
Chat Pages: 1115  1114  1113  1112  1111  1110  1109  1108  1107  1106  1105  1104  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170823 21:08:39